• About
  • Meet The Team
  • Privacy Policy
Thursday, March 4, 2021

Stocks Telegraph
  • Login
  • Home
  • Featured
  • Investing
  • Morning News
  • Mid Day Movers
No Result
View All Result
Stocks Telegraph
No Result
View All Result

BioLineRx (NASDAQ: BLRX) Reports Promising Results Of Motixafortide In Phase III Trial

by Hasnain R
October 30, 2020
in Featured, Mid Day Movers
Share on FacebookShare on Twitter

Shares of BioLineRx Ltd. (NASDAQ: BLRX) traded up 52.03% in the pre-market session after the company has reported the encouraging results from the GENESIS Phase III clinical trial, assessing lead candidate motixafortide for stem cell mobilization in multiple myeloma patients. Initially, the company has planned to enroll 177 patients for the study but the Data Monitoring Committee suggested that the company should stop patients enrollment.

Data Monitoring Committee (DMC) has monitored the primary endpoint of the study and the interim analysis showed the promising results of treatment with motixafortide. As per the suggestion of DMC, the study enrollment is now stopped at 122 patients.

The biotechnology company has announced that the full result of the study along with the safety data will be disclosed once the last patients enrolled reach 100 days of follow-up post-transplantation. It is expected that would occur in the first half of 2021.

BioLineRx Ltd. (NASDAQ: BLRX) shares were trading up 52.03% at $2.250 during the pre-market trading session of Friday. BioLineRx Ltd. (NASDAQ: BLRX) share price went from a low point around $1.06 to briefly over $3.04 in the past 52 weeks. It has a trading volume of 15.23 million during the pre-market trading session. BLRX market cap has remained high, hitting $29.55 million at the time of writing.

The promising results of this study are the greatest achievement of the company. BioLineRx is positive in its opinion that the final results of the study will also support its goal of changing the treatment pattern in autologous stem-cell mobilization, thus positioning motixafortide in combination with G-CSF as the new standard of care in this indication. The GENESIS Trial was started in 2017.

Get The Best Stocks To Trade Every Day!

Join now to get the Stockstelegraph.com pre-market morning brief 100% free

Tags: BioLineRx LtdBLRXData Monitoring CommitteeGENESIS Phase III Trialmotixafortidemyeloma patientsNASDAQ: BLRX

Related Posts

Marinus Pharmaceuticals (NASDAQ: MRNS) Is Popping Today. Here’s Why
Featured

Apple (AAPL) or Alphabet (GOOGL): Which is the Better Stock Pick?

March 1, 2021
ASML Holding (NASDAQ: ASML) Announces 2020 Q3 Results
Featured

What dragged Vistra Corp (VST) about 25% lower?

February 27, 2021
High Flying Plasma Pharmaceuticals as FDA Approves Plasma-based COVID-19 Treatment
Featured

Three Top Coronavirus Stocks to Buy Anytime Soon

February 27, 2021
Tesla Inc. (NASDAQ: TSLA) Reportedly Discuss Nickel Supply Deal With Top Miner BHP
Featured

AMC Entertainment (AMC) Avoids Bankruptcy as Shares Pop Up

January 27, 2021
Top 3 Health Care Stocks that can attract investors in 2021
Featured

Top 3 Health Care Stocks that can attract investors in 2021

January 27, 2021
Sunworks (NASDAQ: SUNW) Stock Is Soaring Today. Here’s Why
Featured

Overstock.com (OSTK) Set to Convert its blockchain-based subsidiary to a limited partnership “Fund”

January 27, 2021
Next Post
10 Of The Best Diagnostics Research Industry Stocks To Buy For 2020

Why Air Industries Group (AIRI) Stocks Jumping Higher Today?

GameStop Corp. (GME) Stock has skyrocketed in the Pre-Market: What’s happening?

Top 3 Reasons Why AzurRx Biopharma Inc [AZRX] is Gaining Bullish Momentum
by ST Staff
February 25, 2021
0

GameStop Corp. (GME) shares have been on a skywalk. The videogame platform seller is captivating the attention in the market...

Read more

Butterfly Network (BFLY): A game changer for medical Imaging devices

Top Performing Stocks Even as Weak Private Payrolls Data Dampens Market Sentiment
by ST Staff
February 24, 2021
0

On January 25, 2011, Jonathan M. Rothberg introduced Butterfly Network (BFLY)‎ that is currently dealing with designing of medical imaging...

Read more

The Three Best Hydrogen Stocks to Watch For in 2021

The Three Best Hydrogen Stocks to Watch For in 2021
by Ali Hassan
February 24, 2021
0

Hydrogen technology is the next big thing that is part of the Go Green movement. In the recent few months,...

Read more

The Three SPAC Stocks to Buy Anytime Soon

by Ali Hassan
February 26, 2021
0

The SPAC stocks have been in action and there are some potential investment opportunities to watch for. A special purpose...

Read more

Early Morning Vibes: Check These 4 Hot Stocks Right Now

GEVO Inc [GEVO]  – A Top Stock To Watch For The Remainder Of 2020
by Hasnain R
February 26, 2021
0

Yesterday the US indices plunged deep into the red again. The last two days have seen a brave recovery, but panic...

Read more
  • About
  • Meet The Team
  • Privacy Policy

© 2020 Stocks Telegraph - All Rights Reserved

No Result
View All Result
  • Home
  • Featured
  • Investing
  • Morning News
  • Mid Day Movers

© 2020 Stocks Telegraph - All Rights Reserved

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Get The Best Stocks To Trade Every Day!

Join now to get the Stockstelegraph.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.